Abbott (NYSE:ABT) landed a contract with the U.S. Defense Dept. to develop a diagnostic assay to detect traumatic brain injuries, the Pentagon said yesterday.
The Chicago-area healthcare giant was the lone bidder for the $35.2 million fixed-price contract, with an estimated completion date of Aug. 31, 2022.
The deal also comes with an immediate $12 million R&D, test and evaluation award for fiscal 2019, according to the Defense Dept.
